Alto Neuroscience (NYSE:ANRO) Earns “Buy” Rating from Chardan Capital

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $30.00 target price on the stock. Chardan Capital’s price target would suggest a potential upside of 10.59% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. BTIG Research raised their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Wall Street Zen downgraded Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. JonesTrading reduced their target price on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Finally, Robert W. Baird reduced their target price on Alto Neuroscience from $41.00 to $38.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Price Performance

NYSE:ANRO traded up $1.54 during trading hours on Wednesday, reaching $27.13. 290,786 shares of the company were exchanged, compared to its average volume of 271,639. The company has a market capitalization of $866.74 million, a P/E ratio of -12.44 and a beta of 2.01. Alto Neuroscience has a 1-year low of $2.12 and a 1-year high of $28.44. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The business has a 50 day moving average of $21.37 and a 200 day moving average of $16.67.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Monday, March 16th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. Research analysts forecast that Alto Neuroscience will post -2.48 EPS for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Hedge funds have recently modified their holdings of the company. Alps Advisors Inc. acquired a new stake in shares of Alto Neuroscience during the 4th quarter valued at $454,000. ExodusPoint Capital Management LP acquired a new stake in shares of Alto Neuroscience during the 4th quarter valued at $334,000. Bridgeway Capital Management LLC boosted its holdings in shares of Alto Neuroscience by 43.5% during the 3rd quarter. Bridgeway Capital Management LLC now owns 77,653 shares of the company’s stock valued at $312,000 after acquiring an additional 23,553 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Alto Neuroscience during the 4th quarter valued at $304,000. Finally, Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience during the 2nd quarter valued at $240,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.